-
Mashup Score: 5265
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Source: www.journalofinfection.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 45Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants - 11 month(s) ago
Bivalent COVID-19 vaccines comprising ancestral Wuhan-Hu-1 (WH1) and the Omicron BA.1 or BA.5 subvariant elicit enhanced serum antibody responses to emerging Omicron subvariants. Here, we characterized the RBD-specific memory B cell (Bmem) response following a fourth dose with a BA.1 or BA.5 bivalent vaccine, in direct comparison with a WH1 monovalent fourth dose. Healthcare workers previously immunized with mRNA or adenoviral vector monovalent vaccines were sampled before and one-month after a fourth dose with a monovalent or a BA.1 or BA.5 bivalent vaccine.
Source: www.journalofinfection.comCategories: General Medicine News, Infectious DiseaseTweet-
still unravelling the complexity of immune responses to the evolving SARS COV 2 variants https://t.co/DgvWItenvm. . https://t.co/c421utGGxd
-
-
Mashup Score: 20Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England - 11 month(s) ago
This study examines clinically confirmed long-COVID symptoms and diagnosis among individuals with COVID in England, aiming to understand prevalence and associated risk factors using electronic health records. To further understand long-COVID, the study also explored differences in risks and symptom profiles in three subgroups: hospitalised, non-hospitalised, and untreated COVID cases.
Source: www.journalofinfection.comCategories: General Medicine News, CardiologistsTweet-
Our latest research: Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England. Led by Han-I Wang & Christina van der Feltz-Cornelis. @kamleshkhunti #LongCovid https://t.co/x2SH6BwHss
-
-
Mashup Score: 0
DPCs can be delivered by non-allergy HCPs. A high proportion of patients with PALs did not progress in the study pathway. Strategies to deliver DPC at optimal points of the care pathway are needed to enhance uptake. Elective settings offer greater opportunities than acute settings for DPC. The safety and simplicity of DPCs lends itself to adoption by healthcare systems beyond the UK, including in resource-limited settings.
Source: www.journalofinfection.comCategories: General Medicine News, Allergy-ImmunologyTweet-
De-labelling 'low risk' patients with penicillin allergy by non-allergy healthcare professionals https://t.co/Q1HhlkLnF6
-
-
Mashup Score: 32
Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.
Source: www.journalofinfection.comCategories: General Medicine News, Critical CareTweet-
The ivermectin result from PRINCIPLE trial is out: https://t.co/roTiQxa7Se https://t.co/lY58niINip
-
-
Mashup Score: 7
Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.
Source: www.journalofinfection.comCategories: General Medicine News, Hem/OncsTweet-
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes https://t.co/1FJOb3ax0r via @GailHayward1 et al https://t.co/m3a8nmI5IQ
-
From a randomized trial, proof that the @Novavax booster induces less acute side effects and more sustained levels of anti-spike IgG antibodies than mRNA shots @moderna_tx @pfizer https://t.co/dl2TkyyjaU Right panel represents anti-spike IgG unadjusted fold reductions at… https://t.co/S9LOz7ISRQ https://t.co/LfxToMnJVo